FDA approves J&J IMAAVY first WAIHA treatment for ages 12+
The FDA approves Johnson & Johnson’s IMAAVY as the first-ever treatment for warm autoimmune hemolytic anemia (WAIHA) in patients aged 12 and older.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.